These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15452301)

  • 1. MRI in acute intermittent maple syrup urine disease.
    Di Rocco M; Biancheri R; Rossi A; Allegri AE; Vecchi V; Tortori-Donati P
    Neurology; 2004 Sep; 63(6):1078. PubMed ID: 15452301
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated excretion of N-acetylated branched-chain amino acids in maple syrup urine disease.
    Lehnert W; Werle E
    Clin Chim Acta; 1988 Feb; 172(1):123-6. PubMed ID: 3359650
    [No Abstract]   [Full Text] [Related]  

  • 3. Contribution of the diffusion-weighted MRI in the diagnosis and follow-up of encephalopathy caused by maple syrup urine disease in a full-term newborn.
    Ferraz-Filho JR; Floriano VH; Quirici MB; Albuquerque RP; Souza AS
    Arq Neuropsiquiatr; 2009 Sep; 67(3A):719-23. PubMed ID: 19722062
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlations between branched-chain amino acids and branched-chain alpha-keto acids in blood in maple syrup urine disease.
    Langenbeck U; Wendel U; Mench-Hoinowski A; Kuschel D; Becker K; Przyrembel H; Bremer HJ
    Clin Chim Acta; 1978 Sep; 88(2):283-91. PubMed ID: 699323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maple-syrup-urine disease.
    Wendel U; Lombeck I; Bremer HJ
    N Engl J Med; 1983 May; 308(18):1100-1. PubMed ID: 6835327
    [No Abstract]   [Full Text] [Related]  

  • 6. New conjugated urinary metabolites in intermediate type maple syrup urine disease.
    Hagenfeldt L; Naglo AS
    Clin Chim Acta; 1987 Oct; 169(1):77-83. PubMed ID: 3677437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the branched chain amino acids and their alpha-ketoacids in maple syrup urine disease.
    Snyderman SE; Goldstein F; Sansaricq C; Norton PM
    Pediatr Res; 1984 Sep; 18(9):851-3. PubMed ID: 6483508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease.
    Schönberger S; Schweiger B; Schwahn B; Schwarz M; Wendel U
    Mol Genet Metab; 2004 May; 82(1):69-75. PubMed ID: 15110325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of muscle fibers in maple syrup urine disease.
    Ferrière G; de Castro M; Rodriguez J
    Acta Neuropathol; 1984; 63(3):249-54. PubMed ID: 6464680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of maple-syrup-urine disease for the first four days of life.
    DiGeorge AM; Rezvani I; Garibaldi LR; Schwartz M
    N Engl J Med; 1982 Dec; 307(24):1492-5. PubMed ID: 7144815
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of maple syrup urine disease on resin coated chromatosheets.
    Kovács J
    Acta Biochim Biophys Acad Sci Hung; 1979; 14(3):119-21. PubMed ID: 547666
    [No Abstract]   [Full Text] [Related]  

  • 12. Nasogastric drip feeding as the only treatment of neonatal maple syrup urine disease.
    Parini R; Sereni LP; Bagozzi DC; Corbetta C; Rabier D; Narcy C; Hubert P; Saudubray JM
    Pediatrics; 1993 Aug; 92(2):280-3. PubMed ID: 8337030
    [No Abstract]   [Full Text] [Related]  

  • 13. Maple syrup urine disease: interrelations between branched-chain amino-, oxo- and hydroxyacids; implications for treatment; associations with CNS dysmyelination.
    Treacy E; Clow CL; Reade TR; Chitayat D; Mamer OA; Scriver CR
    J Inherit Metab Dis; 1992; 15(1):121-35. PubMed ID: 1583867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Maple syrup urine disease: report of a mild variant case and results of dietary treatment].
    Stoppoloni G; Santinelli R; Prisco F; Tolone C; D'Ambrosio M
    Pediatria (Napoli); 1978 Sep; 86(3):409-20. PubMed ID: 754161
    [No Abstract]   [Full Text] [Related]  

  • 15. [Maple syrup urine disease].
    Incesu L; Tasdemir HA; Yazicioglu AK; Belet U; Danaci M
    Radiol Med; 2001 Sep; 102(3):194-6. PubMed ID: 11677467
    [No Abstract]   [Full Text] [Related]  

  • 16. Intermediate maple syrup urine disease: neuroimaging observations in 3 patients from South India.
    Bindu PS; Shehanaz KE; Christopher R; Pal PK; Ravishankar S
    J Child Neurol; 2007 Jul; 22(7):911-3. PubMed ID: 17715290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maple syrup urine disease variant form: presentation with psychomotor retardation and CT scan abnormalities.
    Verdu A; Lopez-Herce J; Pascual-Castroviejo I; Martinez-Bermejo A; Ugarte M; Garcia MJ
    Acta Paediatr Scand; 1985 Sep; 74(5):815-8. PubMed ID: 4050430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Branched-chain alpha-keto acids for the diagnosis of maple-syrup-urine disease.
    Parsons H; Fung E; Snyder FF
    N Engl J Med; 1987 Apr; 316(15):951. PubMed ID: 3821846
    [No Abstract]   [Full Text] [Related]  

  • 19. Valine-toxic intermittent maple syrup urine disease: a previously unrecognized variant.
    Zipf WB; Hieber VC; Allen RJ
    Pediatrics; 1979 Feb; 63(2):286-94. PubMed ID: 440821
    [No Abstract]   [Full Text] [Related]  

  • 20. Thiamine response in maple syrup urine disease.
    Fernhoff PM; Lubitz D; Danner DJ; Dembure PP; Schwartz HP; Hillman R; Bier DM; Elsas LJ
    Pediatr Res; 1985 Oct; 19(10):1011-6. PubMed ID: 3903643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.